PMID- 18397796
OWN - NLM
STAT- MEDLINE
DCOM- 20080617
LR  - 20191210
IS  - 0024-3205 (Print)
IS  - 0024-3205 (Linking)
VI  - 82
IP  - 17-18
DP  - 2008 Apr 23
TI  - Epigallocatechin-3-O-gallate inhibits TNFalpha-induced monocyte chemotactic 
      protein-1 production from vascular endothelial cells.
PG  - 964-8
LID - 10.1016/j.lfs.2008.02.018 [doi]
AB  - Monocyte chemotactic protein-1 (MCP-1) plays a pivotal role in the recruitment of 
      monocytes and thus in the development of inflammatory cardiovascular diseases. 
      Epigallocatechin-3-O-gallate (EGCG), the major catechin derived from green tea, 
      has multiple beneficial effects to reduce cardiovascular disease but the effects 
      of EGCG on vascular endothelial MCP-1 production is not known. In this study, we 
      investigated the mechanisms by which EGCG may inhibit tumor necrosis factor-alpha 
      (TNFalpha)-induced MCP-1 production in bovine coronary artery endothelial cells. 
      TNFalpha increased MCP-1 production in both a concentration and time-dependent 
      manner. Inhibitors of phosphatidylinositol-3-OH kinase (PI-3 kinase), LY294002 
      and wortmannin, decreased TNFalpha-induced MCP-1 production. EGCG prevented 
      TNFalpha-mediated MCP-1 production and reduced phosphorylation of Akt (Ser473). 
      In addition, EGCG attenuated TNFalpha mediated down-regulation of TNFalpha 
      receptor 1 (TNFR1), but not TNFR2. In conclusion, EGCG inhibited TNFalpha-induced 
      MCP-1 production. Moreover, EGCG inhibited Akt phosphorylation as well as TNF 
      activation of TNFR1, which subsequently resulted in reduced MCP-1 production. 
      These data provide a novel mechanism where the green tea flavonoid, EGCG, could 
      provide direct vascular benefits in inflammatory cardiovascular diseases.
FAU - Ahn, Hee Yul
AU  - Ahn HY
AD  - Department of Obstetrics and Gynecology, Perinatal Research Centre, University of 
      Alberta, Edmonton, Canada, T6G 2S2.
FAU - Xu, Yi
AU  - Xu Y
FAU - Davidge, Sandra T
AU  - Davidge ST
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20080308
PL  - Netherlands
TA  - Life Sci
JT  - Life sciences
JID - 0375521
RN  - 0 (Chemokine CCL2)
RN  - 0 (Chromones)
RN  - 0 (Enzyme Inhibitors)
RN  - 0 (Morpholines)
RN  - 0 (Phosphoinositide-3 Kinase Inhibitors)
RN  - 0 (Tea)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 31M2U1DVID (2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one)
RN  - 8R1V1STN48 (Catechin)
RN  - BQM438CTEL (epigallocatechin gallate)
RN  - EC 2.7.11.1 (Oncogene Protein v-akt)
SB  - IM
MH  - Animals
MH  - Catechin/*analogs & derivatives/pharmacology
MH  - Cattle
MH  - Cell Line
MH  - Chemokine CCL2/*biosynthesis
MH  - Chromones/pharmacology
MH  - Endothelial Cells/drug effects/*metabolism
MH  - Endothelium, Vascular/cytology/drug effects/*metabolism
MH  - Enzyme Inhibitors/pharmacology
MH  - Morpholines/pharmacology
MH  - Oncogene Protein v-akt/metabolism
MH  - Phosphoinositide-3 Kinase Inhibitors
MH  - Phosphorylation/drug effects
MH  - Tea/chemistry
MH  - Tumor Necrosis Factor-alpha/*antagonists & inhibitors/*pharmacology
EDAT- 2008/04/10 09:00
MHDA- 2008/06/18 09:00
CRDT- 2008/04/10 09:00
PHST- 2007/10/30 00:00 [received]
PHST- 2008/02/27 00:00 [revised]
PHST- 2008/02/29 00:00 [accepted]
PHST- 2008/04/10 09:00 [pubmed]
PHST- 2008/06/18 09:00 [medline]
PHST- 2008/04/10 09:00 [entrez]
AID - S0024-3205(08)00110-0 [pii]
AID - 10.1016/j.lfs.2008.02.018 [doi]
PST - ppublish
SO  - Life Sci. 2008 Apr 23;82(17-18):964-8. doi: 10.1016/j.lfs.2008.02.018. Epub 2008 
      Mar 8.